盐酸达泊西汀片

Search documents
山东步长制药股份有限公司关于全资子公司经营范围变更的公告
Shang Hai Zheng Quan Bao· 2025-04-09 19:17
Core Viewpoint - The announcement details the changes in the business scope of the wholly-owned subsidiaries of Shandong Buchang Pharmaceutical Co., Ltd., specifically Baoding Tianhao Pharmaceutical Co., Ltd. and Shaanxi Buchang Pharmaceutical Co., Ltd., aimed at improving operational management [1][5]. Group 1: Business Scope Changes - Baoding Tianhao's previous business scope included the production of various pharmaceutical forms, while the new scope allows for broader technical services and drug production [1][2]. - Shaanxi Buchang's business scope has also been expanded to include additional services such as solar energy technology services and contract energy management, alongside its existing pharmaceutical production and wholesale activities [2]. Group 2: Financial Data - As of December 31, 2023, Baoding Tianhao reported total assets of 488.63 million, total liabilities of 319.97 million, and a net asset of 168.66 million, with an annual revenue of 1.21 billion and a net profit of 156.36 million [3]. - For the first nine months of 2024, Baoding Tianhao's total assets were 432.43 million, total liabilities were 288.80 million, net assets were 143.62 million, with a revenue of 906.63 million and a net profit of 131.32 million [3]. - Shaanxi Buchang reported total assets of 3.88 billion, total liabilities of 2.62 billion, and net assets of 1.26 billion as of December 31, 2023, with an annual revenue of 3.34 billion and a net profit of 548.81 million [4]. - As of September 30, 2024, Shaanxi Buchang's total assets were 3.87 billion, total liabilities were 2.98 billion, net assets were 882.65 million, with a revenue of 2.06 billion and a net profit of 254.70 million [4]. Group 3: Authorization and Management - The company has authorized its chairman and president to handle all procedures related to the changes in business scope, including signing relevant documents and submitting government approval applications [4].
东北制药净利润实现四连增 布局生物药赛道打造第二成长曲线
Zheng Quan Ri Bao· 2025-04-03 07:08
Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has shown continuous improvement in profitability, driven by market expansion and innovation in research and development [2][4]. Financial Performance - In the 2024 annual report, the company reported operating revenue of 7.503 billion yuan, a slight decrease year-on-year; net profit reached 410 million yuan, an increase of 14.34%; and non-net profit was 312 million yuan, up 18.97% [2]. - Both net profit and non-net profit have achieved four consecutive years of growth, reaching the highest levels since 2010 [2]. Dividend Distribution - The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [3]. Competitive Advantages - Northeast Pharmaceutical is a significant drug production and export base in China, with integrated production bases for raw materials and formulations [4]. - The company has a diverse product line covering ten major series, including vitamins and anti-infection drugs, with products exported to over 100 countries and regions [4]. - The company increased its R&D investment to 149 million yuan, a year-on-year growth of 7.55% [4][5]. Innovation and Product Development - In 2024, the company successfully obtained one innovative drug candidate and approved five generic drugs for production [5]. - The company received approval for raw material drug listings and registered certificates for several new products, enhancing its product portfolio [5]. - The company’s raw materials, such as L-carnitine and vitamin C, received CEP certification from the European Medicines Agency, allowing sales in the EU high-end pharmaceutical market [5]. Export Business - The export business generated revenue of 902 million yuan in 2024, reflecting a year-on-year increase of 26.30%, with a gross margin growth of 5.89% [6]. Strategic Acquisition - The company is expanding into the biopharmaceutical sector by acquiring Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., focusing on cell immunotherapy technology [7][8]. - Dingcheng Peptide Source has developed a complete technical platform for TCR-T and CAR-T cell therapy products targeting various cancers [7]. - This acquisition is expected to enhance the company's competitiveness in the biopharmaceutical field and accelerate the R&D and commercialization of innovative drugs [8].